Financial Data and Key Metrics Changes - Annual net sales for 2025 grew by $3 billion to $28.4 billion, representing a 12% increase compared to the prior year, with 11% organic growth [11][13] - Adjusted EBITDA was $3.5 billion, a 3% increase year-over-year, reflecting robust sales but offset by higher costs due to tariffs and business investments [11][19] - Free cash flow for the full year was $1.3 billion, impacted by legal settlements and increased tariffs compared to previous years [20] Business Line Data and Key Metrics Changes - Medline Brand segment net sales for the fourth quarter reached $3.7 billion, up 12%, and for the full year, it was $13.7 billion, up 10% [13][14] - Surgical Solutions net sales for the fourth quarter were $1.7 billion, up 12%, driven by strong growth in surgical kitting [14] - Supply Chain Solutions segment delivered $4.1 billion in the fourth quarter, up 18%, and for the full year, net sales were $14.7 billion, up 13% [16] Market Data and Key Metrics Changes - U.S. Acute Care sales grew 16% in the fourth quarter to $5.3 billion and 12% for the full year to $19.5 billion [17] - U.S. Non-Acute sales grew 12% in the fourth quarter to $1.9 billion and 11% for the full year to $7 billion [17] - International sales grew 12% in the fourth quarter to $537 million and 11% for the full year to $2 billion, driven by volume growth in Canada and Europe [18] Company Strategy and Development Direction - The company aims to leverage its scale and customer relationships to create durable, long-term value, focusing on investments in technology, distribution, and partnerships [28] - Continued investment in automation and technology in distribution centers is a priority, with plans to implement AI-powered solutions to enhance supply chain efficiency [9][10] - The company is committed to maintaining a $1 billion annual target for new Prime Vendor signings, reflecting confidence in market conditions [50] Management's Comments on Operating Environment and Future Outlook - Management noted a "crisis of complexity" in healthcare, with hospitals focusing on stabilizing reimbursement profiles and seeking value-driven partnerships [33] - There is an expectation of moderated same-store sales growth in 2026 due to potential impacts from healthcare policy changes [36] - The company anticipates organic sales growth of 8%-9% for 2026, driven by new customer signings and same-store sales growth [21][22] Other Important Information - The company successfully completed its IPO, raising over $7 billion, which strengthened its financial position and reduced net leverage from 4.9x to 3.1x [10][21] - The tariff impact for 2025 was lower than expected at $290 million, with a projected $490 million impact for 2026, reflecting ongoing tariff mitigation strategies [19][68] Q&A Session Summary Question: What are hospital customers' priorities for 2026? - Management highlighted that hospitals are focused on stabilizing reimbursement profiles and seeking value-driven partnerships due to ongoing healthcare complexities [33] Question: How was the guidance for 2026 constructed? - The guidance reflects confidence in achieving strong organic sales growth driven by new customer signings and same-store sales, with some moderation expected due to healthcare policy impacts [40] Question: What is the outlook for Prime Vendor contract wins? - The company reported a record $2.4 billion in new signings for 2025 and remains committed to a $1 billion target for 2026, capitalizing on favorable market conditions [50] Question: What is the potential impact of tariffs on future earnings? - Management indicated that the tariff burden for 2026 is expected to be $490 million, with ongoing evaluations of the tariff landscape to inform future strategies [69] Question: Are there any regulatory changes on the radar? - Management acknowledged ongoing discussions around regulatory changes, particularly related to domestic PPE and Medicare reimbursement, but no immediate impacts were noted [91]

Financial Data and Key Metrics Changes - Annual net sales for 2025 grew by $3 billion to $28.4 billion, representing a 12% increase compared to the prior year, with 11% organic growth [11][13] - Adjusted EBITDA was $3.5 billion, a 3% increase year-over-year, reflecting robust sales but partially offset by higher costs due to tariffs and business investments [11][19] - Free cash flow for the full year was $1.3 billion, impacted by legal settlements and increased tariffs compared to previous years [20] Business Line Data and Key Metrics Changes - Medline Brand segment net sales for the fourth quarter reached $3.7 billion, up 12%, with full-year sales of $13.7 billion, a 10% increase [13][14] - Surgical Solutions net sales for Q4 were $1.7 billion, up 12%, and for the full year, they were $6.2 billion, up 13% [14] - Supply Chain Solutions segment delivered $4.1 billion in Q4, up 18%, and $14.7 billion for the full year, up 13% [16] Market Data and Key Metrics Changes - U.S. Acute Care sales grew 16% in Q4 to $5.3 billion and 12% for the full year to $19.5 billion, driven by new Prime Vendor customers [17] - U.S. Non-Acute sales grew 12% in Q4 to $1.9 billion and 11% for the full year to $7 billion, supported by strong existing customer growth [17] - International sales grew 12% in Q4 to $537 million and 11% for the full year to $2 billion, driven by volume growth in Canada and Europe [18] Company Strategy and Development Direction - The company aims to leverage its scale and customer relationships to create long-term value, focusing on investments in technology, distribution, and partnerships [10][28] - Medline is committed to maintaining a $1 billion annual target for new Prime Vendor signings, reflecting confidence in market conditions [50][62] - The company is exploring M&A opportunities, particularly in non-core assets from competitors, to enhance its market position [82] Management's Comments on Operating Environment and Future Outlook - Management noted a "crisis of complexity" in healthcare, with hospitals focusing on stabilizing reimbursement profiles and seeking value-driven partnerships [33] - There is an expectation of moderate same-store sales growth in 2026 due to potential impacts from healthcare policy changes [36] - The company anticipates organic sales growth of 8%-9% for 2026, driven by new customer signings and same-store sales [21][22] Other Important Information - The company successfully completed its IPO, raising over $7 billion, which strengthened its financial position and reduced net leverage from 4.9x to 3.1x [10][20] - The tariff impact for 2025 was lower than expected at $290 million, with a projected $490 million for 2026, reflecting ongoing tariff mitigation strategies [19][69] Q&A Session Summary Question: What are hospital customers' priorities for 2026? - Management highlighted that hospitals are focused on stabilizing reimbursement profiles and seeking value-driven partnerships due to ongoing healthcare complexities [33] Question: Can you elaborate on the guidance philosophy for 2026? - The guidance reflects confidence in achieving strong organic sales growth driven by new customer signings and same-store sales, despite potential moderation due to healthcare policy impacts [40] Question: How are Prime Vendor contract wins trending? - Management reported strong growth in Prime Vendor signings, particularly in laboratory and diagnostics, and emphasized the commitment to $1 billion in new signings for 2026 [50][62] Question: What are the expectations regarding tariffs? - Management indicated that the tariff environment remains fluid, with a cautious approach to pricing strategies and a focus on mitigating impacts through operational efficiencies [55][57] Question: What are the opportunities for M&A? - The company is optimistic about M&A opportunities, particularly in acquiring non-core assets from competitors and expanding into new markets [82]

Financial Data and Key Metrics Changes - Annual net sales for 2025 grew by $3 billion to $28.4 billion, representing a 12% increase compared to the prior year, with 11% organic growth driven by strong demand from existing customers and new customer signings [10][12] - Adjusted EBITDA was $3.5 billion, a 3% increase year-over-year, reflecting robust sales but partially offset by higher costs of goods due to tariffs and investments in the business [10][18] - Free cash flow for the full year was $1.3 billion, impacted by legal settlements and increased tariffs compared to previous years [19] Business Line Data and Key Metrics Changes - The Medline Brand segment achieved $3.7 billion in net sales for Q4, up 12%, and $13.7 billion for the full year, up 10% [12][10] - Surgical Solutions net sales for Q4 were $1.7 billion, up 12%, driven by strong growth in surgical kitting and other OR products [13] - Supply Chain Solutions segment delivered $4.1 billion in Q4, up 18%, supported by new customer implementations and existing customer growth [15] Market Data and Key Metrics Changes - U.S. Acute Care sales grew 16% in Q4 to $5.3 billion and 12% for the full year to $19.5 billion, driven by new Prime Vendor customers and solid same-store sales growth [16] - U.S. Non-Acute sales grew 12% in Q4 to $1.9 billion and 11% for the full year to $7 billion, supported by strong existing customer growth [16] - International sales grew 12% in Q4 to $537 million and 11% for the full year to $2 billion, driven by volume growth in Canada and Europe [16] Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and financial flexibility post-IPO to invest in future growth and enhance its distribution network through automation and technology [5][9] - Medline is focusing on expanding its product portfolio and enhancing supply chain solutions, including the implementation of AI-powered technologies [9][10] - The company is committed to maintaining a $1 billion annual target for new Prime Vendor signings, reflecting its strategy to capitalize on market conditions and customer needs [46] Management's Comments on Operating Environment and Future Outlook - Management noted that healthcare is facing a crisis of complexity, with hospitals focusing on stabilizing reimbursement profiles and seeking value-driven partnerships [31] - There is an expectation of continued strong sales growth in 2026, with organic sales growth projected in the range of 8%-9% [20] - The tariff environment remains fluid, and management is evaluating the impact of recent tariff changes while maintaining a cautious approach [21][55] Other Important Information - The company ended the year with a successful IPO, raising over $7 billion, which strengthened its financial position and reduced net leverage from 4.9x to 3.1x [9][20] - Capital expenditures for the full year were $447 million, focusing on capacity expansion and technology upgrades [19] Q&A Session Summary Question: What are hospital customers' priorities for 2026? - Management highlighted that hospitals are focused on stabilizing reimbursement profiles and seeking value-driven partnerships due to ongoing complexities in healthcare [31][32] Question: How was the guidance for 2026 constructed? - The guidance reflects confidence in achieving strong organic sales growth driven by new customer signings and same-store sales growth, despite potential moderation due to external factors [39][40] Question: What is the outlook for Prime Vendor contract wins? - Management confirmed a commitment to $1 billion in new Prime Vendor signings for 2026, with favorable market conditions expected to support this goal [46][48] Question: What is the impact of tariffs on future earnings? - The company expects a $200 million tariff headwind in 2026, with ongoing evaluations of the tariff landscape to inform future strategies [21][55] Question: Are there any changes in market dynamics due to competitor transitions? - Management noted that market conditions remain similar to 2025, with opportunities arising from competitors' strategic shifts and ongoing consolidation in healthcare [61][62]